← Back
Data updated: Nov 8, 2026
DIFGEN PHARMS
Generics Pharmaceuticals
DIFGEN PHARMS is a generic drug manufacturer with 13 FDA-approved products.
1997
Since
13
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
DIFGEN PHARMS's Key Drugs
DIFGEN PHARMS's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE — its most strategically important drugs approved in the last 15 years.
DIFGEN PHARMS's Recent FDA Approvals
New NDA/BLA approvals for DIFGEN PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
DIFGEN PHARMS's Therapeutic Areas
Disease areas where DIFGEN PHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
DIFGEN PHARMS Pipeline Snapshot
Active clinical trials for DIFGEN PHARMS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1997-10-20
- Latest
- 2026-08-14
- Applications
- 6